ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
会议论文

Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.

Ren, Zhenggang; Guo, Yabing; Bai, Yuxian; Ying, Jieer; Meng, Zhiqiang; Chen, Zhendong; Gu, Shanzhi; Zhang, Jingdong; Liang, Jun; Hou, Xinfang; Li, Wei; Xu, Aibing; Hao, Chunyi; Zhang, Jian; Xing, Ruijun; Zhang, Xinyu; Zhang, Dan; Chan, Stephen Lam复旦大学; 安徽医科大学; 北京大学; 吉林大学; 哈尔滨医科大学; 郑州大学; 中国医科大学; 中国科学院研究生院; 1
Genitourinary Cancers Symposium2023-2-1
3被引9阅读
引用收藏
分享
相关
加载中…
  • Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).
    Zhao, Hong; Zhou, Aiping; Tu, Jianfei; Bai, Yuxian; Mao, Xianhai; Song, Tianqiang; Li, Bo; Dai, Wenxiang; Lv, Jing; Wang, Jufeng; Che, Xu; Liu, Lianxin; Zhang, Lianhai; Wu, Wei; Cai, JianqiangAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
  • A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results.
    Xing, Baocai; Da, Xu; Zhang, Yanqiao; Ma, YueAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 1
  • Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
    Qin, Shukui; Chen, Zhendong; Fang, Weijia; Ren, Zhenggang; Xu, Ruocai; Ryoo, Baek-Yeol; Meng, Zhiqiang; Bai, Yuxian; Chen, Xiaoming; Liu, Xiufeng; Xiao, Juxiang; Ho, Gwo Fuang; Mao, Yimin; Ye, Xing; Ying, Jieer; Li, Jianfeng; Zhong, Wen Yan; Zhou, Yu; Siegel, Abby B.; Hao, ChunyiASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 73
查看全部 →

会议信息

会议名称
Genitourinary Cancers Symposium
会议日期
2023-01-19 至 2023-01-21
论文集名
JOURNAL OF CLINICAL ONCOLOGY
发表日期
2023-02-01
起止页码
578-578
资助标注
Zai Lab (Shanghai) Co., Ltd.
收录
ISTP · SCIE

作者

  • R

    Ren, Zhenggang (第一作者)

  • G

    Guo, Yabing

查看全部 18 位作者收起作者
  • B

    Bai, Yuxian

  • Y

    Ying, Jieer

  • M

    Meng, Zhiqiang

  • C

    Chen, Zhendong

  • G

    Gu, Shanzhi

  • Z

    Zhang, Jingdong

  • L

    Liang, Jun

  • H

    Hou, Xinfang

  • L

    Li, Wei

  • X

    Xu, Aibing

  • H

    Hao, Chunyi

  • Z

    Zhang, Jian

  • X

    Xing, Ruijun

  • Z

    Zhang, Xinyu

  • Z

    Zhang, Dan

  • C

    Chan, Stephen Lam

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417